View Filing Data

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2016	Jan. 17, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Trading Symbol	PTIE
Entity Registrant Name	PAIN THERAPEUTICS INC
Entity Central Index Key	0001069530
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		46,141,935
Entity Public Float			$ 84,608,935
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 16,615	$ 31,299
Marketable securities	2,099
Other current assets	356	392
Total current assets	19,070	31,691
Property and equipment, net	232	215
Other assets		12
Total assets	19,302	31,918
Current liabilities:
Accounts payable	303	1,034
Accrued development expense	27	894
Accrued compensation and benefits	335	623
Total current liabilities	665	2,551
Noncurrent liabilities
Total liabilities	665	2,551
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.001 par value; 10,000,000 shares authorized, none issued and outstanding
Common stock, $.001 par value; 120,000,000 shares authorized; 46,141,935 and 45,756,117 shares issued and outstanding at December 31, 2016 and 2015, respectively	46	46
Additional paid-in capital	164,079	159,959
Accumulated other comprehensive income
Accumulated deficit	(145,488)	(130,638)
Total stockholders' equity	18,637	29,367
Total liabilities and stockholders' equity	$ 19,302	$ 31,918

Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating expenses:
Research and development	$ 9,176	$ 9,100	$ 7,306
General and administrative	5,781	5,102	5,127
Total operating expenses	14,957	14,202	12,433
Operating loss	(14,957)	(14,202)	(12,433)
Interest income	107	57	47
Net loss	$ (14,850)	$ (14,145)	$ (12,386)
Net loss per share, basic and diluted	$ (0.33)	$ (0.31)	$ (0.27)
Shares used in computing net loss per share, basic and diluted	45,638	45,356	45,269

Statements Of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2013	$ 45,000	$ 152,363,000	$ 1,000	$ (104,107,000)	$ 48,302,000
Balance, Shares at Dec. 31, 2013	45,510,038
Issuance of common stock pursuant to exercise of stock options	$ 1,000	378,000			379,000
Issuance of common stock pursuant to exercise of stock options, shares	246,079
Stock options for employees		3,619,000			3,619,000
Stock options for non-employees		142,000			142,000
Net loss				(12,386,000)	(12,386,000)
Balance at Dec. 31, 2014	$ 46,000	156,502,000	1,000	(116,493,000)	40,056,000
Balance, Shares at Dec. 31, 2014	45,756,117
Stock options for employees		3,453,000			3,453,000
Stock options for non-employees		4,000			4,000
Other comprehensive loss			$ (1,000)		(1,000)
Net loss				(14,145,000)	(14,145,000)
Balance at Dec. 31, 2015	$ 46,000	159,959,000		(130,638,000)	$ 29,367,000
Balance, Shares at Dec. 31, 2015	45,756,117
Issuance of common stock pursuant to exercise of stock options, shares
Stock options for employees		3,467,000			$ 3,467,000
Stock options for non-employees		25,000			25,000
Performance Awards and related non-cash stock-related compensation, shares	$ 485,000	842,000			842,000
Performance Awards related to statutory taxes, shares	(99,182)	(214,000)			(214,000)
Net loss				(14,850,000)	(14,850,000)
Balance at Dec. 31, 2016	$ 46,000	$ 164,079,000		$ (145,488,000)	$ 18,637,000
Balance, Shares at Dec. 31, 2016	46,141,935

Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
Statements Of Cash Flows - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows used in operating activities:
Net loss	$ (14,850)	$ (14,145)	$ (12,386)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash stock-based compensation	4,334	3,457	3,761
Depreciation and amortization	58	45	15
Non-cash net interest income	(8)	(4)	(2)
Changes in operating assets and liabilities:
Other current assets	86	(87)	26
Other non-current assets	12		(12)
Accounts payable	(711)	841	(272)
Accrued development expense	(867)	869	(616)
Accrued compensation and benefits	(288)	(29)	(60)
Other current liabilities			(3)
Net cash used in operating activities	(12,234)	(9,053)	(9,549)
Cash flows provided by (used in) investing activities:
Purchases of property and equipment	(75)	(195)	(80)
Purchases of marketable securities	(4,141)	(3,847)	(2,598)
Maturities of marketable securities	2,050	3,850	3,850
Net cash provided by (used in) investing activities	(2,166)	(192)	1,172
Cash flows provided by (used in) financing activities:
Proceeds from issuance of common stock, net			379
Statutory taxes for net exercise of Performance Awards	(214)
Deferred financing costs	(70)	(46)
Net cash provided by (used in) financing activities	(284)	(46)	379
Net decrease in cash and cash equivalents	(14,684)	(9,291)	(7,998)
Cash and cash equivalents at beginning of the period	31,299	40,590	48,588
Cash and cash equivalents at end of the period	$ 16,615	$ 31,299	$ 40,590

Summary Of Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Summary Of Significant Accounting Policies [Abstract]

Summary Of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.

Proceeds from Grants

We record proceeds from a grant from the NIH as a reduction to our research and development expenses. We received $1.5 million in 2016 and $0.2 million in 2015 from this grant.

Cash Equivalents, Marketable Securities and Concentration of Credit Risk

We invest in cash equivalents and marketable securities. We consider highly-liquid financial instruments with original maturities of three months or less to be cash equivalents. Our marketable securities include interest-bearing financial instruments, generally consisting of corporate or government securities.

We are subject to credit risk due to our investments. Our investment policy allows for investments in marketable securities with active secondary or resale markets, establishes diversification and credit quality requirements and limits investments by maturity and issuer. We maintain our investments at one financial institution.

A change in prevailing interest rates may cause the fair value of the investment to fluctuate. We don’t recognize an impairment charge related to this type of fluctuation because the fluctuation is temporary and eliminated by the time an investment matures. We would recognize an impairment charge if and when we determine that a decline in the fair value below the amortized cost of an investment is other-than-temporary. We consider various factors in determining whether to recognize an impairment charge, including any adverse changes in the investees’ financial condition, how long the fair value has been below the amortized cost and whether it is more likely than not that we would elect to or be required to sell the marketable security before its anticipated recovery.

We may elect to sell marketable securities before they mature. We hold these investments as “available for sale” and include these investments in our Balance Sheets as current assets, even though the contractual maturity of a particular investment may be beyond one year.

Fair Value Measurements

We report our cash equivalents and marketable securities at fair value as Level 1, Level 2 or Level 3 using the following inputs:

Level 1 includes quoted prices in active markets. We base the fair value of money market funds and U.S. treasury securities on Level 1 inputs.

Level 2 includes significant observable inputs, such as quoted prices for identical or similar investments, or other inputs that are observable and can be corroborated by observable market data for similar securities. We use market pricing and other observable market inputs obtained from third-party providers. We use the bid price to establish fair value where a bid price is available. We base the fair value of our marketable securities on Level 2 inputs.

Level 3 includes unobservable inputs that are supported by little or no market activity. We do not have any investments where the fair value is based on Level 3 inputs.

We include unrealized gains or losses on our investments as Accumulated other comprehensive income (loss) in the Stockholders’ equity section of our Balance Sheets. We include changes in net unrealized gains or losses in our Statements of Comprehensive Income (Loss). We would recognize significant realized gains and losses on a specific identification basis as other income in our Statements of Operations.

Business Segments

We report segment information based on how we internally evaluate the operating performance of our business units, or segments. Our operations are confined to one business segment: the development of novel drugs.

Stock-based Compensation

We recognize non-cash expense for the fair value of all stock options and other share-based awards. We use the Black-Scholes option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. For options granted to employees and directors, we recognize the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally four years. For options granted to non-employees, we remeasure the fair value expense using Black-Scholes each reporting period.

We have granted share-based awards that vest upon achievement of certain performance criteria, or Performance Awards. We multiply the number of Performance Awards by the fair market value of our common stock on the date of grant to calculate the fair value of each award. We estimate an implicit service period for achieving performance criteria for each award. We recognize the resulting fair value as expense over the implicit service period when we conclude that achieving the performance criteria is probable. We periodically review and update as appropriate our estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.

Net Loss per Share

Basic net loss per share is computed on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding equity awards and warrants. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands):



	Years ended December 31,
	2016		2015		2014
Numerator:
Net loss	$	(14,850)	$	(14,145)	$	(12,386)
Denominator:
Shares used in computing net loss per share, basic and diluted		45,638		45,356		45,269
Net loss per share, basic and diluted	$	(0.33)	$	(0.31)	$	(0.27)
Dilutive common shares excluded from net loss per share, diluted		17,745		17,421		10,625

We excluded weighted equity awards outstanding to purchase common stock from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.

Income Taxes

We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income or loss for each full fiscal year. In 2016, we adopted ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. The adoption of this standard had no impact on our financial statements for 2016.

We have accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these deferred tax assets with a valuation allowance.

We may in the future determine that certain deferred tax assets will likely be realized, in which case we will reduce our valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, we may recognize a benefit from income taxes in our Statement of Operations in that period.

We classify interest recognized pursuant to our deferred tax assets as interest expense, when appropriate.

Recent Accounting Pronouncements

We reviewed recently issued accounting pronouncements and plan to adopt those that are applicable to us. We do not expect the adoption of these pronouncements to have a material impact on our financial position, results of operations or cash flows.

Cash And Cash Equivalents And Marketable Securities

12 Months Ended

Dec. 31, 2016

Cash And Cash Equivalents And Marketable Securities [Abstract]

Cash And Cash Equivalents And Marketable Securities

4. Cash and Cash Equivalents and Marketable Securities

Cash, cash equivalents and marketable securities held as available-for-sale consisted of the following (in thousands):



	Cash, Cash Equivalents and Marketable Securities
	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Accrued Interest		Total Value
December 31, 2016
Cash	$	1,434	$	—	$	—	$	1,434	$	—	$	1,434
Cash equivalents		12,783		—		—		12,783		—		12,783
Commercial paper		4,497		—		—		4,497		—		4,497
Corporate securities		—		—		—		—		—		—
	$	18,714	$	—	$	—	$	18,714	$	—	$	18,714
Reported as:
Cash and cash equivalents	$	16,615		—		—	$	16,615	$	—	$	16,615
Marketable securities		2,099		—		—		2,099		—		2,099
	$	18,714	$	—	$	—	$	18,714	$	—	$	18,714
Maturities:
Matures in one year or less	$	18,714	$	—	$	—	$	18,714	$	—	$	18,714
Matures one to three years		—		—		—		—		—		—
	$	18,714	$	—	$	—	$	18,714	$	—	$	18,714

December 31, 2015
Cash	$	273	$	—	$	—	$	273	$	—	$	273
Cash equivalents		22,630		—		—		22,630		—		22,630
Commercial paper		8,396		1		(1)		8,396		—		8,396
	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Reported as:
Cash and cash equivalents	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Marketable securities		—		—		—		—		—		—
	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Maturities:
Matures in one year or less	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Matures one to three years		—		—		—		—		—		—
	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299

To date we have not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value.

Our assets measured at fair value were (in thousands):



	Level 1		Level 2		Level 3		Total
December 31, 2016
Cash and cash equivalents	$	14,217	$	—	$	—	$	14,217
Commercial paper		—		4,497		—		4,497
	$	14,217	$	4,497	$	—	$	18,714
December 31, 2015
Cash and cash equivalents	$	22,903	$	—	$	—	$	22,903
Commercial paper		—		8,396		—		8,396
	$	22,903	$	8,396	$	—	$	31,299

Stockholders' Equity And Stock-Based Compensation

12 Months Ended

Dec. 31, 2016

Stockholders' Equity And Stock-Based Compensation [Abstract]

Stockholders' Equity And Stock-Based Compensation

6. Stockholders' Equity and Stock-Based Compensation

Preferred Stock

Our Board of Directors has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.

2008 Equity Incentive Plan

Under our 2008 Equity Incentive Plan, or 2008 Equity Plan, our employees, directors and consultants may receive share-based awards, including grants of stock options and Performance Awards. Our Board of Directors or a designated Committee of the Board is responsible for administration of the 2008 Equity Plan and determines the terms and conditions of each option granted, consistent with the terms of the plan. The 2008 Equity Plan terminates in December 2017.

Share-based awards generally expire ten years from the date of grant. Cancelled stock options become available for reissuance. As of December 31, 2016, we have 3.4 million shares reserved and available to be issued under the 2008 Equity Incentive Plan.

The 2008 Equity Plan provides for the automatic grant of options to purchase shares of common stock to outside directors. On the date of each annual stockholders’ meeting, each outside director is automatically granted an option to purchase 50,000 shares of common stock. These options have a ten-year life, have an exercise price of 100% of the fair market value of the stock on the date of grant, and become exercisable as to 25% of the shares on the anniversary of its date of grant provided the optionee continues to serve as a director on such dates.

When stock options or Performance Awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. We then use our cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.

Stock Options

The following summarizes information about stock option activity during 2016:


	Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
				In years	In millions
Outstanding as of December 31, 2015	18,515,254	$	3.75	5.1	$	—
Granted	355,000	$	2.36
Exercised	—	$	—
Canceled	(1,825,767)	$	4.87
Outstanding as of December 31, 2016	17,044,487	$	3.60	4.8	$	—
Vested and expected to vest at December 31, 2016	17,044,487	$	3.60	4.8	$	—
Exercisable at December 31, 2016	13,430,734	$	3.89	3.8	$	—

The following summarizes information about stock options at December 31, 2016 by a range of exercise prices:


				Options outstanding				Options exercisable
					Weighted
					average	Weighted			Weighted
				Number of	remaining	average		Number of	average
Range of exercise prices				outstanding	contractual	exercise		vested	exercise
From		To		options	life (in years)	price		options	price
$	1.72	$	1.87	3,580,000	8.4	$	1.81	1,384,165	$	1.79
$	2.03	$	2.58	3,454,819	5.1	$	2.45	2,767,527	$	2.48
$	2.69	$	4.39	4,791,636	3.2	$	3.69	4,717,469	$	3.70
$	4.59	$	5.00	3,735,079	3.5	$	4.87	3,111,329	$	4.86
$	5.20	$	7.65	1,482,953	3.5	$	7.12	1,450,244	$	7.16
				17,044,487	4.8	$	3.60	13,430,734	$	3.89

We use Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of our common stock. For options granted to employees and directors, we used certain factors to value each stock option granted, which resulted in a weighted average fair value of options granted during 2016, 2015 and 2014, as follows:


	2016	2015	2014
Volatility	72%	74% to 76%	68% to 74%
Risk-free interest rates	1% to 2%	1% to 2%	1% to 2%
Expected life of option	7 years	7 years	7 years
Dividend yield	zero	zero	zero
Forfeiture rate	zero	zero	zero
Weighted average fair value of stock options granted	$1.60	$1.29	$2.32

Volatility is based on reviews of the historical volatility of our common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is zero because we do not anticipate paying cash dividends in the foreseeable future. We estimate forfeitures and adjust this estimate periodically based in part on the extent to which actual forfeitures differ from our estimates.

For options granted to non-employees, we estimate the fair value of stock options granted using factors similar to those used for stock options granted to employees and directors and appropriate for the terms underlying the stock options granted to non-employees. We re-measure the compensation expense for options granted to non-employees each reporting period.

As of December 31, 2016, we expect to recognize compensation expense of $5.9 million related to non-vested options held by employees and directors over the weighted average remaining recognition period of 2.2 years.

Performance Awards

The following summarizes information about Performance Award activity during 2016:


		Number of Performance Awards
Outstanding as of December 31, 2015		1,889,465
Granted		150,000
Vested Performance Awards		(485,000)
Canceled		—
Outstanding as of December 31, 2016		1,554,465

Vested Performance Awards resulted from the resubmission of the NDA for REMOXY. No outstanding Performance Awards are vested. If and when outstanding Performance Awards vest, we would recognize $4.7 million in non-cash stock-based compensation expense. These Performance Awards expire between 2022 and 2026.

Stock-Based Compensation Expense

The following summarizes information about non-cash stock-based compensation expense, in thousands:



	Years ended December 31,
	2016		2015		2014

Research and development
Vesting of stock options	$	1,313	$	1,198	$	1,624
Vesting of Performance Awards		438		—		—
		1,751		1,198		1,624
General and administrative
Vesting of stock options		2,179		2,259		2,137
Vesting of Performance Awards		404		—		—
		2,583		2,259		2,137
Total non-cash stock-based compensation expenses
Vesting of stock options		3,492		3,457		3,761
Vesting of Performance Awards		842		—		—
	$	4,334	$	3,457	$	3,761

Non-cash stock-related compensation expense related to vesting of Performance Awards was associated with the resubmission of the NDA for REMOXY.

Capital on Demand Sales Agreement

In December 2015, we entered into an Capital on Demand™ Sales Agreement with JonesTrading Institutional Services, or the ATM Agreement, relating to the offering of up to 10.0 million shares of our Common Stock in “at the market” offerings. We did not issue any shares under the ATM Agreement in 2016 or 2015. We deferred financing costs of $0.1 million at December 31, 2016 and 2015 paid in connection with entering into the ATM Agreement.

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Taxes [Abstract]

Income Taxes

8. Income Taxes

We did not provide for income taxes in 2016 and 2015 because we had a net operating loss for tax purposes in those years and the tax benefit that would have resulted from the statutory rate was fully offset by the valuation allowance.

Deferred tax assets and valuation allowance

Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. We offset our deferred tax assets by a valuation allowance because we are uncertain about the timing and amount of any future profits. Significant components of our deferred tax assets are as follows (in thousands):


	December 31,
	2016		2015
Deferred tax assets:
Net operating loss carryforwards	$	22,300	$	17,100
Stock-related compensation		9,100		10,600
Research & development credit carryforwards		6,200		6,000
Other		200		500
		37,800		34,200
Valuation allowance		(37,800)		(34,200)
	$	—	$	—

As of the beginning of 2016, we increased both our net operating loss carryforwards and our valuation allowance by $0.9 million when we adopted ASU 2016-09 for certain tax deductions associated with stock option transactions greater than the stock-related compensation expense in our financial statements. The valuation allowance increased by $3.6 million in 2016 and $3.4 million in 2015.

Our pre-tax net operating loss carryforwards of $65.6 million are federal and expire between 2029 and 2036. As of December 31, 2016, we had federal research and development tax credits of approximately $10.4 million, which expire in the years 2023 through 2036.

Unrecognized tax benefits

We have unrecognized tax benefits related to tax credits. We added to our unrecognized tax benefits in 2016 and 2015 as follows (in thousands):



	2016		2015
Beginning balance	$	4,000	$	3,900
Additions based on tax positions related to the current year		200		100
Ending balance	$	4,200	$	4,000

Selected Quarterly Financial Data

12 Months Ended

Dec. 31, 2016

Selected Quarterly Financial Data [Abstract]

Selected Quarterly Financial Data

11. Selected Quarterly Financial Data (Unaudited) (in thousands, except per share data)


	Quarters Ended
	March 31		June 30		September 30		December 31
2016
Total revenue	$	—	$	—	$	—	$	—
Net loss	$	(5,795)	$	(3,015)	$	(3,518)	$	(2,522)
Basic and diluted net loss per share	$	(0.13)	$	(0.07)	$	(0.08)	$	(0.06)
2015
Total revenue	$	—	$	—	$	—	$	—
Net loss	$	(2,583)	$	(3,374)	$	(3,671)	$	(4,517)
Basic and diluted net loss per share	$	(0.06)	$	(0.07)	$	(0.08)	$	(0.10)
2014
Total revenue	$	—	$	—	$	—	$	—
Net loss	$	(3,450)	$	(3,246)	$	(3,534)	$	(2,156)
Basic and diluted net loss per share	$	(0.08)	$	(0.07)	$	(0.08)	$	(0.05)

Summary Of Significant Accounting Policies (Policy)

12 Months Ended

Dec. 31, 2016

Summary Of Significant Accounting Policies [Abstract]

Use of Estimates

Proceeds from Grants

We record proceeds from a grant from the NIH as a reduction to our research and development expenses. We received $1.5 million in 2016 and $0.2 million in 2015 from this grant.

Cash Equivalents, Marketable Securities and Concentration of Credit Risk

Fair Value Measurements

We report our cash equivalents and marketable securities at fair value as Level 1, Level 2 or Level 3 using the following inputs:

Level 1 includes quoted prices in active markets. We base the fair value of money market funds and U.S. treasury securities on Level 1 inputs.

Level 3 includes unobservable inputs that are supported by little or no market activity. We do not have any investments where the fair value is based on Level 3 inputs.

Business Segments

Stock-based Compensation

Net Loss per Share



	Years ended December 31,
	2016		2015		2014
Numerator:
Net loss	$	(14,850)	$	(14,145)	$	(12,386)
Denominator:
Shares used in computing net loss per share, basic and diluted		45,638		45,356		45,269
Net loss per share, basic and diluted	$	(0.33)	$	(0.31)	$	(0.27)
Dilutive common shares excluded from net loss per share, diluted		17,745		17,421		10,625

Income Taxes

We classify interest recognized pursuant to our deferred tax assets as interest expense, when appropriate.

Recent Accounting Pronouncements

Cash And Cash Equivalents And Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2016

Cash And Cash Equivalents And Marketable Securities [Abstract]

Cash, Cash Equivalents And Marketable Securities



	Cash, Cash Equivalents and Marketable Securities
	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Accrued Interest		Total Value
December 31, 2016
Cash	$	1,434	$	—	$	—	$	1,434	$	—	$	1,434
Cash equivalents		12,783		—		—		12,783		—		12,783
Commercial paper		4,497		—		—		4,497		—		4,497
Corporate securities		—		—		—		—		—		—
	$	18,714	$	—	$	—	$	18,714	$	—	$	18,714
Reported as:
Cash and cash equivalents	$	16,615		—		—	$	16,615	$	—	$	16,615
Marketable securities		2,099		—		—		2,099		—		2,099
	$	18,714	$	—	$	—	$	18,714	$	—	$	18,714
Maturities:
Matures in one year or less	$	18,714	$	—	$	—	$	18,714	$	—	$	18,714
Matures one to three years		—		—		—		—		—		—
	$	18,714	$	—	$	—	$	18,714	$	—	$	18,714

December 31, 2015
Cash	$	273	$	—	$	—	$	273	$	—	$	273
Cash equivalents		22,630		—		—		22,630		—		22,630
Commercial paper		8,396		1		(1)		8,396		—		8,396
	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Reported as:
Cash and cash equivalents	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Marketable securities		—		—		—		—		—		—
	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Maturities:
Matures in one year or less	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Matures one to three years		—		—		—		—		—		—
	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299

Assets Measured At Fair Value On Recurring Basis



	Level 1		Level 2		Level 3		Total
December 31, 2016
Cash and cash equivalents	$	14,217	$	—	$	—	$	14,217
Commercial paper		—		4,497		—		4,497
	$	14,217	$	4,497	$	—	$	18,714
December 31, 2015
Cash and cash equivalents	$	22,903	$	—	$	—	$	22,903
Commercial paper		—		8,396		—		8,396
	$	22,903	$	8,396	$	—	$	31,299

Stockholders' Equity And Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2016

Stockholders' Equity And Stock-Based Compensation [Abstract]

Stock Option Activity


	Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
				In years	In millions
Outstanding as of December 31, 2015	18,515,254	$	3.75	5.1	$	—
Granted	355,000	$	2.36
Exercised	—	$	—
Canceled	(1,825,767)	$	4.87
Outstanding as of December 31, 2016	17,044,487	$	3.60	4.8	$	—
Vested and expected to vest at December 31, 2016	17,044,487	$	3.60	4.8	$	—
Exercisable at December 31, 2016	13,430,734	$	3.89	3.8	$	—

Information About Stock Options Outstanding


				Options outstanding				Options exercisable
					Weighted
					average	Weighted			Weighted
				Number of	remaining	average		Number of	average
Range of exercise prices				outstanding	contractual	exercise		vested	exercise
From		To		options	life (in years)	price		options	price
$	1.72	$	1.87	3,580,000	8.4	$	1.81	1,384,165	$	1.79
$	2.03	$	2.58	3,454,819	5.1	$	2.45	2,767,527	$	2.48
$	2.69	$	4.39	4,791,636	3.2	$	3.69	4,717,469	$	3.70
$	4.59	$	5.00	3,735,079	3.5	$	4.87	3,111,329	$	4.86
$	5.20	$	7.65	1,482,953	3.5	$	7.12	1,450,244	$	7.16
				17,044,487	4.8	$	3.60	13,430,734	$	3.89

Weighted Average Fair Value Of Options Granted


	2016	2015	2014
Volatility	72%	74% to 76%	68% to 74%
Risk-free interest rates	1% to 2%	1% to 2%	1% to 2%
Expected life of option	7 years	7 years	7 years
Dividend yield	zero	zero	zero
Forfeiture rate	zero	zero	zero
Weighted average fair value of stock options granted	$1.60	$1.29	$2.32

Performance Award activity


		Number of Performance Awards
Outstanding as of December 31, 2015		1,889,465
Granted		150,000
Vested Performance Awards		(485,000)
Canceled		—
Outstanding as of December 31, 2016		1,554,465

Summary Of Non-Cash Stock-Based Compensation



	Years ended December 31,
	2016		2015		2014

Research and development
Vesting of stock options	$	1,313	$	1,198	$	1,624
Vesting of Performance Awards		438		—		—
		1,751		1,198		1,624
General and administrative
Vesting of stock options		2,179		2,259		2,137
Vesting of Performance Awards		404		—		—
		2,583		2,259		2,137
Total non-cash stock-based compensation expenses
Vesting of stock options		3,492		3,457		3,761
Vesting of Performance Awards		842		—		—
	$	4,334	$	3,457	$	3,761

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Taxes [Abstract]

Schedule Of Deferred Tax Assets And Valuation Allowance


	December 31,
	2016		2015
Deferred tax assets:
Net operating loss carryforwards	$	22,300	$	17,100
Stock-related compensation		9,100		10,600
Research & development credit carryforwards		6,200		6,000
Other		200		500
		37,800		34,200
Valuation allowance		(37,800)		(34,200)
	$	—	$	—

Schedule Of Unrecognized Tax Benefits



	2016		2015
Beginning balance	$	4,000	$	3,900
Additions based on tax positions related to the current year		200		100
Ending balance	$	4,200	$	4,000

Selected Quarterly Financial Data (Tables)

12 Months Ended

Dec. 31, 2016

Selected Quarterly Financial Data [Abstract]

Quarterly Financial Information


	Quarters Ended
	March 31		June 30		September 30		December 31
2016
Total revenue	$	—	$	—	$	—	$	—
Net loss	$	(5,795)	$	(3,015)	$	(3,518)	$	(2,522)
Basic and diluted net loss per share	$	(0.13)	$	(0.07)	$	(0.08)	$	(0.06)
2015
Total revenue	$	—	$	—	$	—	$	—
Net loss	$	(2,583)	$	(3,374)	$	(3,671)	$	(4,517)
Basic and diluted net loss per share	$	(0.06)	$	(0.07)	$	(0.08)	$	(0.10)
2014
Total revenue	$	—	$	—	$	—	$	—
Net loss	$	(3,450)	$	(3,246)	$	(3,534)	$	(2,156)
Basic and diluted net loss per share	$	(0.08)	$	(0.07)	$	(0.08)	$	(0.05)

Cash And Cash Equivalents And Marketable Securities (Cash, Cash Equivalents And Marketable Securities) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Amortized Cost Basis	$ 2,099
Cash and cash equivalents	16,615	$ 31,299	$ 40,590	$ 48,588
Cash and cash equivalents, Short Term Investment, Amortized Cost	18,714	31,299
Cash and cash equivalents, Short Term Investment Unrealized Gains		1
Cash and cash equivalents, Short Term Investment Unrealized Losses		(1)
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Estimated Fair Value, Marketable securities	2,099
Cash and cash equivalents, Short Term Investment, Fair Value	18,714	31,299
Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value, Marketable securities	2,099
Cash and cash equivalents, Short Term Investment, Fair Value	18,714	31,299
Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash	1,434	273
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Fair Value	1,434	273
Cash [Member] \| Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	1,434	273
Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash equivalents	12,783	22,630
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Fair Value	12,783	22,630
Cash Equivalents [Member] \| Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	12,783	22,630
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Amortized Cost Basis	4,497	8,396
Available-for-sale securities, Gross Unrealized Gains		1
Available-for-sale securities, Gross Unrealized Losses		(1)
Accrued Interest
Estimated Fair Value, Marketable securities	4,497	8,396
Commercial Paper [Member] \| Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value, Marketable securities	4,497	8,396
Corporate Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash And Cash Equivalents, Reported Value [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents	16,615	31,299
Available-for-sale securities, Gross Unrealized Gains		1
Available-for-sale securities, Gross Unrealized Losses		(1)
Accrued Interest
Cash and cash equivalents, Fair Value	16,615	31,299
Cash And Cash Equivalents, Reported Value [Member] \| Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	16,615	31,299
Matures In One Year Or Less [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Amortized Cost	18,714	31,299
Available-for-sale securities, Gross Unrealized Gains		1
Available-for-sale securities, Gross Unrealized Losses		(1)
Accrued Interest
Cash and cash equivalents, Short Term Investment, Fair Value	18,714	31,299
Matures In One Year Or Less [Member] \| Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Fair Value	18,714	31,299
Matures One To Three Years [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest

Stockholders' Equity And Stock-Based Compensation (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%
Offering of common stock shares	120,000,000	120,000,000
2008 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance	3,400,000
Common stock shares granted to outside directors	50,000
Expiration period of stock options granted	10 years
Fair market value percent	100.00%
Options exercisable percentage	25.00%
Compensation costs prior to forfeiture	$ 5.9
Weighted average remaining recognition period	2 years 2 months 12 days
ATM Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Offering of common stock shares		10,000,000
Deferred financing costs	$ 0.1	$ 0.1
Performance Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional stock compensation expense	$ 4.7
Performance Awards vested	0
Performance Awards [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance awards expiration date	Dec. 31, 2026
Performance Awards [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance awards expiration date	Dec. 31, 2022

Stockholders' Equity And Stock-Based Compensation (Stock Option Activity) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Stockholders' Equity And Stock-Based Compensation [Abstract]
Outstanding as of December 31, 2015	18,515,254
Granted	355,000
Exercised
Canceled	(1,825,767)
Outstanding as of December 31, 2016	17,044,487	18,515,254
Number of Options, Vested and expected to vest at December 31, 2016	17,044,487
Number of Options, Exercisable at December 31, 2016	13,430,734
Outstanding as of December 31, 2015, Weighted Average Exercise Price	$ 3.75
Weighted Average Exercise Price, Granted	2.36
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Cancelled	4.87
Outstanding as of December 31, 2016, Weighted Average Exercise Price	3.60	$ 3.75
Weighted Average Exercise Price, Vested and expected to vest at December 31, 2016	3.60
Weighted Average Exercise Price, Exercisable at December 31, 2016	$ 3.89
Weighted Average Remaining Contractual Term at December 31, 2015	4 years 9 months 18 days	5 years 1 month 6 days
Weighted Average Remaining Contractual Term, Vested and expected to vest at December 31, 2016	4 years 9 months 18 days
Weighted Average Remaining Contractual Term, Exercisable at December 31, 2016	3 years 9 months 18 days

Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)	12 Months Ended
	Dec. 31, 2016 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of outstanding options, Options outstanding \| shares	17,044,487
Weighted average remaining contractual life (in years), Options outstanding	4 years 9 months 18 days
Weighted average exercise price, Options outstanding	$ 3.60
Number of vested options, Options exercisable \| shares	13,430,734
Weighted average exercise price, Options exercisable	$ 3.89
$1.72 - $1.87 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	1.72
Range of exercise prices, Maximum	$ 1.87
Number of outstanding options, Options outstanding \| shares	3,580,000
Weighted average remaining contractual life (in years), Options outstanding	8 years 4 months 24 days
Weighted average exercise price, Options outstanding	$ 1.81
Number of vested options, Options exercisable \| shares	1,384,165
Weighted average exercise price, Options exercisable	$ 1.79
$2.03 - $2.58 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	2.03
Range of exercise prices, Maximum	$ 2.58
Number of outstanding options, Options outstanding \| shares	3,454,819
Weighted average remaining contractual life (in years), Options outstanding	5 years 1 month 6 days
Weighted average exercise price, Options outstanding	$ 2.45
Number of vested options, Options exercisable \| shares	2,767,527
Weighted average exercise price, Options exercisable	$ 2.48
$2.69 - $4.39 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	2.69
Range of exercise prices, Maximum	$ 4.39
Number of outstanding options, Options outstanding \| shares	4,791,636
Weighted average remaining contractual life (in years), Options outstanding	3 years 2 months 12 days
Weighted average exercise price, Options outstanding	$ 3.69
Number of vested options, Options exercisable \| shares	4,717,469
Weighted average exercise price, Options exercisable	$ 3.70
$4.59 - $5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	4.59
Range of exercise prices, Maximum	$ 5.00
Number of outstanding options, Options outstanding \| shares	3,735,079
Weighted average remaining contractual life (in years), Options outstanding	3 years 6 months
Weighted average exercise price, Options outstanding	$ 4.87
Number of vested options, Options exercisable \| shares	3,111,329
Weighted average exercise price, Options exercisable	$ 4.86
$5.20 - $7.65 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	5.20
Range of exercise prices, Maximum	$ 7.65
Number of outstanding options, Options outstanding \| shares	1,482,953
Weighted average remaining contractual life (in years), Options outstanding	3 years 6 months
Weighted average exercise price, Options outstanding	$ 7.12
Number of vested options, Options exercisable \| shares	1,450,244
Weighted average exercise price, Options exercisable	$ 7.16

Stockholders' Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Stockholders' Equity And Stock-Based Compensation [Abstract]
Volatility	72.00%
Volatility, Minimum		74.00%	68.00%
Volatility, Maximum		76.00%	74.00%
Risk-free interest rates, Minimum	1.00%	1.00%	1.00%
Risk-free interest rates, Maximum	2.00%	2.00%	2.00%
Expected life of option	7 years	7 years	7 years
Dividend yield	0.00%	0.00%	0.00%
Forfeiture rate	0.00%	0.00%	0.00%
Weighted average fair value of stock options granted	$ 1.60	$ 1.29	$ 2.32

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	46,141,935	45,756,117
Common stock, shares outstanding	46,141,935	45,756,117

General	12 Months Ended
General	Dec. 31, 2016
General [Abstract]
General	1. General Pain Therapeutics, Inc. develops proprietary drugs that offer significant improvements to patients and healthcare professionals. We generally focus our drug development efforts on disorders of the nervous system, such as chronic pain. In the course of our development activities, we have sustained cumulative operating losses. There are no assurances that additional financing will be available on favorable terms, or at all.

Collaboration Agreements	12 Months Ended
Collaboration Agreements	Dec. 31, 2016
Collaboration Agreements [Abstract]
Collaboration Agreements	3. Collaboration Agreements Durect Corporation We have an exclusive, worldwide Development and License Agreement, or the Durect Agreement, with Durect to use a patented controlled-release technology that forms the basis for REMOXY. Under the terms of the Durect Agreement, we are solely responsible for clinical development, Durect is responsible for furnishing suitable laboratory facilities, equipment and personnel during pre-clinical phases of development and we and Durect are jointly responsible for certain pre-clinical activities. We reimburse Durect’s expenses and have made milestone payments based on the achievement of certain clinical or regulatory milestones.

Property And Equipment	12 Months Ended
Property And Equipment	Dec. 31, 2016
Property And Equipment [Abstract]
Property And Equipment	5. Property and Equipment Property and equipment includes furniture and equipment with a purchase value of $1.0 million at December 31, 2016 and $0.9 million at December 31, 2015. Depreciation is recognized using the straight-line method over the expected life of the property and equipment. Accumulated depreciation was $0.7 million at both December 31, 2016 and December 31, 2015. Depreciation and amortization expense was not significant in 2016, 2015 and 2014.

Employee 401(k) Benefit Plan	12 Months Ended
Employee 401(k) Benefit Plan	Dec. 31, 2016
Employee 401(k) Benefit Plan [Abstract]
Employee 401(k) Benefit Plan	7. Employee 401(k) Benefit Plan We have a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the first day of the month after hire and may contribute up to the current statutory limits under Internal Revenue Service regulations. The 401(k) plan permits us to make additional matching contributions on behalf of all employees. Through December 31, 2016, we have not made any matching contributions to the 401(k) plan.

Leases And Commitments	12 Months Ended
Leases And Commitments	Dec. 31, 2016
Leases And Commitments [Abstract]
Leases And Commitments	9. Leases and Commitments We believe that our facilities are adequate and suitable for our current needs. We lease approximately 6,000 square feet of office space pursuant to a non-cancelable operating lease in Austin, TX that expires in December 2017. Future minimum lease payments are $0.1 million in 2017. Rent expense was $0.1 million in 2016, 2015 and 2014. We conduct our product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. We have contractual arrangements with these organizations, however these contracts are cancelable on thirty days’ notice and our obligations under these contracts are largely based on services performed.

Legal Proceedings	12 Months Ended
Legal Proceedings	Dec. 31, 2016
Legal Proceedings [Abstract]
Legal Proceedings	10. Legal proceedings KB Partners I, L.P., Individually and On Behalf of All Others Similarly Situated v. Pain Therapeutics, Inc., Remi Barbier, Nadav Friedmann and Peter S. Roddy, No. 11-cv-01034 (W.D. Tex.) On December 2, 2011, a purported class action was filed against us and our executive officers in the U.S. District Court for the Western District of Texas alleging, among other things, violations of Section 10(b), Rule 10b-5, and Section 20(a) of the Exchange Act. At a preliminary settlement conference on September 1, 2016, the Court approved a Stipulated Settlement Agreement. Following a hearing on December 16, 2016, the Court issued its final approval for the Stipulated Settlement Agreement and administratively closed the docket.

Summary Of Significant Accounting Policies (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2016 USD ($) segment	Dec. 31, 2015 USD ($)
Summary Of Significant Accounting Policies [Abstract]
Contractual maturity of a particular investment	1 year
Reduction to research and development expense \| $	$ 1.5	$ 0.2
Number of business segments \| segment	1
Vesting period of stock options	4 years

Summary Of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Numerator:
Net loss	$ (2,522)	$ (3,518)	$ (3,015)	$ (5,795)	$ (4,517)	$ (3,671)	$ (3,374)	$ (2,583)	$ (2,156)	$ (3,534)	$ (3,246)	$ (3,450)	$ (14,850)	$ (14,145)	$ (12,386)
Denominator:
Shares used in computing net loss per share, basic and diluted													45,638	45,356	45,269
Net loss per share, basic and diluted	$ (0.06)	$ (0.08)	$ (0.07)	$ (0.13)	$ (0.10)	$ (0.08)	$ (0.07)	$ (0.06)	$ (0.05)	$ (0.08)	$ (0.07)	$ (0.08)	$ (0.33)	$ (0.31)	$ (0.27)
Dilutive common shares excluded from net loss per share, diluted													17,745	17,421	10,625

Cash And Cash Equivalents And Marketable Securities (Assets Measured At Fair Value On Recurring Basis) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 18,714	$ 31,299
Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	14,217	22,903
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	4,497	8,396
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	14,217	22,903
Level 1 [Member] \| Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	14,217	22,903
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	4,497	8,396
Level 2 [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	4,497	8,396
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] \| Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value

Property And Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Accumulated depreciation	$ 0.7	$ 0.7
Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, purchase value	$ 1.0	$ 0.9

Stockholders' Equity And Stock-Based Compensation (Performance Award Activity) (Details) - Performance Awards [Member]	12 Months Ended
	Dec. 31, 2016 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding as of December 31, 2015	1,889,465
Granted	150,000
Vested Performance Awards	0
Outstanding as of December 31, 2016	1,554,465
Remoxy [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested Performance Awards	(485,000)

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Operating Loss Carryforwards [Line Items]
Valuation allowance increase (decrease)	$ 3.6	$ 3.4
ASU 2016-09 [Member]
Operating Loss Carryforwards [Line Items]
Valuation allowance increase (decrease)	0.9
Federal [Member]
Operating Loss Carryforwards [Line Items]
Pre-tax net operating loss carryforwards	65.6
Federal research and development tax credits	$ 10.4
Federal [Member] \| Minimum [Member]
Operating Loss Carryforwards [Line Items]
Expiration date of pre-tax net operating loss carryforwards	Jan. 01, 2029
Expiration date of federal research and development tax credits	Jan. 01, 2023
Federal [Member] \| Maximum [Member]
Operating Loss Carryforwards [Line Items]
Expiration date of pre-tax net operating loss carryforwards	Jan. 01, 2036
Expiration date of federal research and development tax credits	Jan. 01, 2036

Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Abstract]
Net operating loss carryforwards	$ 22,300	$ 17,100
Stock-related compensation	9,100	10,600
Research & development credit carryforwards	6,200	6,000
Other	200	500
Total deferred tax assets	37,800	34,200
Valuation allowance	(37,800)	(34,200)
Net deferred tax assets

Leases And Commitments (Narrative) (Details) $ in Millions	12 Months Ended
Leases And Commitments (Narrative) (Details) $ in Millions	Dec. 31, 2016 USD ($) ft²	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Leases And Commitments [Line Items]
Office space \| ft²	6,000
Rent expense	$ 0.1	$ 0.1	$ 0.1
Austin, TX [Member]
Leases And Commitments [Line Items]
Operating lease expiration year	2017-12
Future minimum lease payments in 2017	$ 0.1